FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
← catalyst calendarNCT07446322 · readout in 376 d
Sponsored by Oncolytics Biotech (industry) · ONCY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
60estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-30 | actual | When the study began enrolling |
| Primary completion | 2027-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ras-mutated Metastatic Colorectal Cancer
- mCRC
- MSS Metastatic Colorectal Cancer
Interventions
- Drug: Bevacizumab — also filed as Avastin
- Drug: FOLFIRI
- Drug: Pelareorep
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR)
measured At week 8
Permalink · ONCY's whole pipeline · Catalyst calendar · Every registered study · What changed